Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.73
MRK's Cash to Debt is ranked higher than
65% of the 1159 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.17 vs. MRK: 0.73 )
MRK' s 10-Year Cash to Debt Range
Min: 0.37   Max: 1.93
Current: 0.73

0.37
1.93
Equity to Asset 0.50
MRK's Equity to Asset is ranked higher than
62% of the 1084 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.58 vs. MRK: 0.50 )
MRK' s 10-Year Equity to Asset Range
Min: 0.37   Max: 0.53
Current: 0.5

0.37
0.53
Interest Coverage 7.75
MRK's Interest Coverage is ranked higher than
53% of the 613 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 120.76 vs. MRK: 7.75 )
MRK' s 10-Year Interest Coverage Range
Min: 3.31   Max: 44.62
Current: 7.75

3.31
44.62
F-Score: 5
Z-Score: 3.93
M-Score: -2.91
WACC vs ROIC
5.26%
7.99%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 12.51
MRK's Operating margin (%) is ranked higher than
79% of the 1110 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.84 vs. MRK: 12.51 )
MRK' s 10-Year Operating margin (%) Range
Min: 5.15   Max: 43.77
Current: 12.51

5.15
43.77
Net-margin (%) 26.98
MRK's Net-margin (%) is ranked higher than
96% of the 1110 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.50 vs. MRK: 26.98 )
MRK' s 10-Year Net-margin (%) Range
Min: 1.87   Max: 47.03
Current: 26.98

1.87
47.03
ROE (%) 27.69
MRK's ROE (%) is ranked higher than
95% of the 1139 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.62 vs. MRK: 27.69 )
MRK' s 10-Year ROE (%) Range
Min: 1.52   Max: 48.6
Current: 27.69

1.52
48.6
ROA (%) 13.08
MRK's ROA (%) is ranked higher than
93% of the 1170 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.52 vs. MRK: 13.08 )
MRK' s 10-Year ROA (%) Range
Min: 0.79   Max: 18.45
Current: 13.08

0.79
18.45
ROC (Joel Greenblatt) (%) 33.31
MRK's ROC (Joel Greenblatt) (%) is ranked higher than
87% of the 1165 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.08 vs. MRK: 33.31 )
MRK' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 10.88   Max: 123.42
Current: 33.31

10.88
123.42
Revenue Growth (3Y)(%) -2.40
MRK's Revenue Growth (3Y)(%) is ranked higher than
60% of the 940 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.80 vs. MRK: -2.40 )
MRK' s 10-Year Revenue Growth (3Y)(%) Range
Min: -16.5   Max: 21.4
Current: -2.4

-16.5
21.4
EBITDA Growth (3Y)(%) 19.10
MRK's EBITDA Growth (3Y)(%) is ranked higher than
85% of the 851 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.70 vs. MRK: 19.10 )
MRK' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -17.6   Max: 44.7
Current: 19.1

-17.6
44.7
EPS Growth (3Y)(%) 26.30
MRK's EPS Growth (3Y)(%) is ranked higher than
90% of the 809 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.70 vs. MRK: 26.30 )
MRK' s 10-Year EPS Growth (3Y)(%) Range
Min: -42.7   Max: 73.8
Current: 26.3

-42.7
73.8
» MRK's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

MRK Guru Trades in Q2 2014

George Soros 86,800 sh (New)
Joel Greenblatt 126,844 sh (+3456.04%)
Ken Fisher 6,464,243 sh (+791.55%)
Jim Simons 795,534 sh (+305.47%)
Paul Tudor Jones 13,266 sh (+163.48%)
Pioneer Investments 4,256,501 sh (+81.49%)
Manning & Napier Advisors, Inc 380,192 sh (+7.55%)
Ruane Cunniff 4,609 sh (+4.54%)
Murray Stahl 48,271 sh (+0.46%)
James Barrow 22,793,207 sh (+0.24%)
Robert Bruce 261,500 sh (unchged)
Richard Snow 5,410 sh (unchged)
Prem Watsa 12,000 sh (unchged)
Steven Cohen 17,200 sh (unchged)
Brian Rogers 6,625,700 sh (unchged)
Mario Gabelli 160,316 sh (unchged)
David Dreman Sold Out
Charles Brandes 2,434,531 sh (-0.68%)
Irving Kahn 1,120,074 sh (-0.74%)
Tom Russo 4,386 sh (-3.31%)
Vanguard Health Care Fund 33,889,948 sh (-4.85%)
Bill Frels 107,546 sh (-5.84%)
Jeff Auxier 149,734 sh (-8.81%)
NWQ Managers 84,311 sh (-9.59%)
Dodge & Cox 35,960,137 sh (-10.01%)
Jean-Marie Eveillard 1,755,082 sh (-21.54%)
RS Investment Management 861,075 sh (-48.40%)
Jeremy Grantham 340,971 sh (-86.46%)
» More
Q3 2014

MRK Guru Trades in Q3 2014

Ray Dalio 14,141 sh (New)
Stanley Druckenmiller 329,600 sh (New)
Steven Cohen 321,100 sh (+1766.86%)
Joel Greenblatt 536,550 sh (+323.00%)
Paul Tudor Jones 31,725 sh (+139.15%)
Ruane Cunniff 4,784 sh (+3.80%)
Mario Gabelli 162,706 sh (+1.49%)
Robert Bruce 265,000 sh (+1.34%)
Ken Fisher 6,533,475 sh (+1.07%)
RS Investment Management 861,075 sh (unchged)
Prem Watsa 12,000 sh (unchged)
Brian Rogers 6,625,700 sh (unchged)
Pioneer Investments 4,327,974 sh (unchged)
George Soros Sold Out
James Barrow 22,769,088 sh (-0.11%)
NWQ Managers 83,811 sh (-0.59%)
Richard Snow 5,375 sh (-0.65%)
Manning & Napier Advisors, Inc 377,389 sh (-0.74%)
Bill Frels 106,735 sh (-0.75%)
Irving Kahn 1,109,189 sh (-0.97%)
Jim Simons 787,634 sh (-0.99%)
Tom Russo 4,336 sh (-1.14%)
Vanguard Health Care Fund 33,420,748 sh (-1.38%)
Jeff Auxier 147,484 sh (-1.50%)
Dodge & Cox 35,057,668 sh (-2.51%)
Murray Stahl 46,821 sh (-3.00%)
Charles Brandes 2,320,288 sh (-4.69%)
Jean-Marie Eveillard 1,083,826 sh (-38.25%)
Signature Select Canadian Fund 163,400 sh (-45.44%)
Jeremy Grantham 118,890 sh (-65.13%)
» More
Q4 2014

MRK Guru Trades in Q4 2014

PRIMECAP Management 700,000 sh (New)
Joel Greenblatt 1,045,652 sh (+94.88%)
Paul Tudor Jones 53,076 sh (+67.30%)
Ray Dalio 20,541 sh (+45.26%)
Vanguard Health Care Fund 35,788,048 sh (+7.08%)
Manning & Napier Advisors, Inc 399,235 sh (+5.79%)
Ken Fisher 6,640,510 sh (+1.64%)
Bill Frels 107,684 sh (+0.89%)
James Barrow 22,856,934 sh (+0.39%)
NWQ Managers 83,828 sh (+0.02%)
Richard Snow 5,375 sh (unchged)
Ruane Cunniff 4,784 sh (unchged)
Tom Russo 4,336 sh (unchged)
Brian Rogers 6,625,700 sh (unchged)
Prem Watsa 12,000 sh (unchged)
Stanley Druckenmiller Sold Out
Murray Stahl 46,801 sh (-0.04%)
Jeff Auxier 147,334 sh (-0.10%)
Charles Brandes 2,306,840 sh (-0.58%)
Robert Bruce 259,400 sh (-2.11%)
Steven Cohen 311,600 sh (-2.96%)
Dodge & Cox 33,616,093 sh (-4.11%)
Irving Kahn 1,052,807 sh (-5.08%)
Mario Gabelli 144,408 sh (-11.25%)
RS Investment Management 674,675 sh (-21.65%)
Pioneer Investments 3,201,729 sh (-26.02%)
Jim Simons 575,624 sh (-26.92%)
Jeremy Grantham 13,022 sh (-89.05%)
Jean-Marie Eveillard 9,050 sh (-99.16%)
» More
Q1 2015

MRK Guru Trades in Q1 2015

Vanguard Health Care Fund 40,096,948 sh (+12.04%)
Mario Gabelli 160,943 sh (+11.45%)
Ken Fisher 6,679,499 sh (+0.59%)
Brian Rogers 6,625,700 sh (unchged)
Manning & Napier Advisors, Inc 398,354 sh (-0.22%)
Irving Kahn 1,029,815 sh (-2.18%)
» More
» Details

Insider Trades

Latest Guru Trades with MRK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Merck & Co Inc

Bill Nygren Comments on Merck - Apr 10, 2014

We eliminated our position in Merck (MRK) as the shares appreciated to our estimate of fair value.

From Bill Nygren (Trades, Portfolio)'s Oakmark Fund first quarter 2014 commentary.

Check out Bill Nygren latest stock trades

Top Ranked Articles about Merck & Co Inc

Vanguard Adds to Four of Its Largest Stakes
It isn’t surprising that nearly 95% of Vanguard Health Care Fund (Trades, Portfolio)’s holdings are related to health care, drug manufacturing and medical technology. But there has been some jockeying for position within the Fund’s portfolio in the early months of 2015. Read more...
A Look at the Top Five Medical Stocks Held in the Vanguard Portfolio
Over the duration of the third quarter the Vanguard Health Care Fund added two new stocks to its holdings. The fund now holds on to 89 stocks valued at $39.18 billion. The following companies are Vanguard's top portfolio holdings. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 14.70
MRK's P/E(ttm) is ranked higher than
95% of the 1281 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 72.00 vs. MRK: 14.70 )
MRK' s 10-Year P/E(ttm) Range
Min: 6.67   Max: 139.89
Current: 14.7

6.67
139.89
Forward P/E 15.77
MRK's Forward P/E is ranked higher than
100% of the 1281 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. MRK: 15.77 )
N/A
PE(NRI) 14.80
MRK's PE(NRI) is ranked higher than
95% of the 1281 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 68.20 vs. MRK: 14.80 )
MRK' s 10-Year PE(NRI) Range
Min: 6.65   Max: 133.39
Current: 14.8

6.65
133.39
P/B 3.50
MRK's P/B is ranked higher than
69% of the 1281 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.24 vs. MRK: 3.50 )
MRK' s 10-Year P/B Range
Min: 1.72   Max: 7.27
Current: 3.5

1.72
7.27
P/S 4.20
MRK's P/S is ranked higher than
100% of the 1281 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.24 vs. MRK: 4.20 )
MRK' s 10-Year P/S Range
Min: 2.01   Max: 5.48
Current: 4.2

2.01
5.48
PFCF 32.40
MRK's PFCF is ranked higher than
86% of the 1281 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3458.60 vs. MRK: 32.40 )
MRK' s 10-Year PFCF Range
Min: 7.8   Max: 86.81
Current: 32.4

7.8
86.81
POCF 22.71
MRK's POCF is ranked higher than
85% of the 1281 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 44.77 vs. MRK: 22.71 )
MRK' s 10-Year POCF Range
Min: 6.33   Max: 35.75
Current: 22.71

6.33
35.75
EV-to-EBIT 31.24
MRK's EV-to-EBIT is ranked higher than
80% of the 1281 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 46.13 vs. MRK: 31.24 )
MRK' s 10-Year EV-to-EBIT Range
Min: 8.5   Max: 104.2
Current: 31.24

8.5
104.2
PEG 3.70
MRK's PEG is ranked higher than
89% of the 1281 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. MRK: 3.70 )
MRK' s 10-Year PEG Range
Min: 0.54   Max: 57.09
Current: 3.7

0.54
57.09
Shiller P/E 23.10
MRK's Shiller P/E is ranked higher than
93% of the 1281 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. MRK: 23.10 )
MRK' s 10-Year Shiller P/E Range
Min: 8.26   Max: 25.39
Current: 23.1

8.26
25.39
Current Ratio 1.77
MRK's Current Ratio is ranked higher than
65% of the 1155 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.10 vs. MRK: 1.77 )
MRK' s 10-Year Current Ratio Range
Min: 1.12   Max: 2.04
Current: 1.77

1.12
2.04
Quick Ratio 1.47
MRK's Quick Ratio is ranked higher than
69% of the 1155 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.60 vs. MRK: 1.47 )
MRK' s 10-Year Quick Ratio Range
Min: 0.81   Max: 1.66
Current: 1.47

0.81
1.66
Days Inventory 111.52
MRK's Days Inventory is ranked higher than
79% of the 1281 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 153.39 vs. MRK: 111.52 )
MRK' s 10-Year Days Inventory Range
Min: 50.6   Max: 332.33
Current: 111.52

50.6
332.33
Days Sales Outstanding 58.42
MRK's Days Sales Outstanding is ranked higher than
83% of the 1281 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 90.94 vs. MRK: 58.42 )
MRK' s 10-Year Days Sales Outstanding Range
Min: 44.42   Max: 92.3
Current: 58.42

44.42
92.3

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 3.00
MRK's Dividend Yield is ranked higher than
86% of the 686 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.32 vs. MRK: 3.00 )
MRK' s 10-Year Dividend Yield Range
Min: 2.51   Max: 6.68
Current: 3

2.51
6.68
Dividend Payout 0.43
MRK's Dividend Payout is ranked higher than
96% of the 1281 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. MRK: 0.43 )
MRK' s 10-Year Dividend Payout Range
Min: 0.27   Max: 5.43
Current: 0.43

0.27
5.43
Dividend growth (3y) 4.30
MRK's Dividend growth (3y) is ranked higher than
71% of the 476 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.00 vs. MRK: 4.30 )
MRK' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 14.8
Current: 4.3

0
14.8
Yield on cost (5-Year) 3.58
MRK's Yield on cost (5-Year) is ranked higher than
83% of the 693 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.55 vs. MRK: 3.58 )
MRK' s 10-Year Yield on cost (5-Year) Range
Min: 3   Max: 7.97
Current: 3.58

3
7.97
Share Buyback Rate 1.80
MRK's Share Buyback Rate is ranked higher than
94% of the 768 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -1.60 vs. MRK: 1.80 )
MRK' s 10-Year Share Buyback Rate Range
Min: 1.8   Max: -13
Current: 1.8

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 11.30
MRK's Price/Tangible Book is ranked higher than
52% of the 1281 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.30 vs. MRK: 11.30 )
MRK' s 10-Year Price/Tangible Book Range
Min: 3.19   Max: 3735
Current: 11.3

3.19
3735
Price/DCF (Projected) 1.60
MRK's Price/DCF (Projected) is ranked higher than
93% of the 1281 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. MRK: 1.60 )
MRK' s 10-Year Price/DCF (Projected) Range
Min: 0.85   Max: 3.04
Current: 1.6

0.85
3.04
Price/Median PS Value 1.30
MRK's Price/Median PS Value is ranked higher than
77% of the 1281 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.50 vs. MRK: 1.30 )
MRK' s 10-Year Price/Median PS Value Range
Min: 0.78   Max: 2.02
Current: 1.3

0.78
2.02
Price/Graham Number 2.70
MRK's Price/Graham Number is ranked higher than
82% of the 1281 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.40 vs. MRK: 2.70 )
MRK' s 10-Year Price/Graham Number Range
Min: 1.17   Max: 14.83
Current: 2.7

1.17
14.83
Earnings Yield (Greenblatt) 3.20
MRK's Earnings Yield (Greenblatt) is ranked higher than
74% of the 1155 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.80 vs. MRK: 3.20 )
MRK' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1   Max: 11.8
Current: 3.2

1
11.8
Forward Rate of Return (Yacktman) 5.83
MRK's Forward Rate of Return (Yacktman) is ranked higher than
73% of the 586 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.86 vs. MRK: 5.83 )
MRK' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -6.2   Max: 22.1
Current: 5.83

-6.2
22.1

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Traded in other countries:0QAH.UK, MRK.France, 6MK.Germany, MRCK34.Brazil, MRK.Mexico, MRK.Argentina, MRK.Chile, MRK.Switzerland,
Merck & Co Inc was incorporated in New Jersey in 1970. The Company is a health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures. The Company's operations are mainly managed on a products basis and are comprised of four operating segments, which are the Pharmaceutical, Animal Health, Consumer Care and Alliances segments, and one reportable segment, which is the Pharmaceutical segment. The Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Vaccine products consist of preventive pediatric, adolescent and adult vaccines, primarily administered at physician offices. The Company sells these human health vaccines primarily to physicians, wholesalers, physician distributors and government entities. The Company also has animal health operations that discover, develop, manufacture and market animal health products, including vaccines, which the Company sells to veterinarians, distributors and animal producers. Additionally, the Company has consumer care operations that develop, manufacture and market over-the-counter, foot care and sun care products, which are sold through wholesale and retail drug, food chain and mass merchandiser outlets, as well as club stores and specialty channels. The Company's competitors include other worldwide research-based pharmaceutical companies, smaller research companies with more limited therapeutic focus, and generic drug and consumer health care manufacturers. The Company's activities, including research, preclinical testing, clinical trials and manufacturing and marketing its products, are subject to regulation by numerous federal, state and local governmental authorities in the United States, including the FDA, and by foreign regulatory authorities, including the European Commission.
» More Articles for MRK

Headlines

Articles On GuruFocus.com
Vanguard Adds to Four of Its Largest Stakes May 04 2015 
Biogen Making A Breakthrough In Treating Alzheimer’s May 02 2015 
Robert Bruce's Top Growth Stocks Apr 13 2015 
Gilead Experiencing Bumpy Ride Despite Strong Fundamentals Apr 03 2015 
Pfizer In The Process Of Making Path Breaking Vaccine Mar 18 2015 
Johnson & Johnson Unfazed By $25 Million Fine Mar 13 2015 
Bayer Goes Into Disinvestment Mode Due To Falling Profit Numbers Feb 27 2015 
Abner Herrman's Top Three Holdings Feb 26 2015 
PRIMECAP Management's New Positions Feb 13 2015 
The Dogs of the Dow Get Off to a Sluggish Start in 2015 Feb 11 2015 

More From Other Websites
Big Pharma Q1 Earnings Beat Put Pharma ETFs in Focus - ETF News And Commentary May 06 2015
Study Finds Merck Millipore’s Strat-M® Synthetic Membrane Comparable to Human and Animal Skin for... May 06 2015
Healthcare Mid-Day Winners and Losers: May 04, 2015 May 05 2015
Healthcare Winners and Losers: May 04, 2015 May 05 2015
Top Credit Suisse Major Pharma Stock Picks to Buy May 05 2015
The Cancer Drug Market Just Hit $100 Billion And Could Jump 50% In Four Years May 05 2015
Global cancer drug spending hits $100 billion in 2014 - IMS Health May 05 2015
Global cancer drug spending hits $100 billion in 2014-IMS Health May 05 2015
Global cancer drug spending hits $100 billion in 2014-IMS Health May 05 2015
MEDIA-Global annual spending on cancer drugs surges to $100 bln - FT May 04 2015
Vanguard Adds to Four of Its Largest Stakes May 04 2015
The 4 Stocks That Buoyed the Dow on Monday May 04 2015
Murky Situation Over the Merck Name Plagues Two Drug Makers May 04 2015
Weak Q1 Earnings Have Some Investors Worried.......Should You Be? May 04 2015
A tale of two Mercks: Confusion mounts over shared brand name May 03 2015
The Advantages of Owning Individual Stocks May 03 2015
Top picks in health care May 01 2015
Gilead Soothes Price War Worry With Q1 Results May 01 2015
Bank Of America Reviews Gilead Earnings May 01 2015
Merck deal boosts sales but not income at Bayer Apr 30 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK